Literature DB >> 12499181

Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin.

Marc Pfister1, Liping Zhang, Margareta Hammarlund-Udenaes, Lewis B Sheiner, Cynthia M Gerber, Martin G Täuber, Philippe Cottagnoud.   

Abstract

The goals of the present study were to model the population kinetics of in vivo influx and efflux processes of grepafloxacin at the serum-cerebrospinal fluid (CSF) barrier and to propose a simulation-based approach to optimize the design of dose-finding trials in the meningitis rabbit model. Twenty-nine rabbits with pneumococcal meningitis receiving grepafloxacin at 15 mg/kg of body weight (intravenous administration at 0 h), 30 mg/kg (at 0 h), or 50 mg/kg twice (at 0 and 4 h) were studied. A three-compartment population pharmacokinetic model was fit to the data with the program NONMEM (Nonlinear Mixed Effects Modeling). Passive diffusion clearance (CL(diff)) and active efflux clearance (CL(active)) are transfer kinetic modeling parameters. Influx clearance is assumed to be equal to CL(diff), and efflux clearance is the sum of CL(diff), CL(active), and bulk flow clearance (CL(bulk)). The average influx clearance for the population was 0.0055 ml/min (interindividual variability, 17%). Passive diffusion clearance was greater in rabbits receiving grepafloxacin at 15 mg/kg than in those treated with higher doses (0.0088 versus 0.0034 ml/min). Assuming a CL(bulk) of 0.01 ml/min, CL(active) was estimated to be 0.017 ml/min (11%), and clearance by total efflux was estimated to be 0.032 ml/min. The population kinetic model allows not only to quantify in vivo efflux and influx mechanisms at the serum-CSF barrier but also to analyze the effects of different dose regimens on transfer kinetic parameters in the rabbit meningitis model. The modeling-based approach also provides a tool for the simulation and prediction of various outcomes in which researchers might be interested, which is of great potential in designing dose-finding trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499181      PMCID: PMC149016          DOI: 10.1128/AAC.47.1.138-143.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics.

Authors:  M Hammarlund-Udenaes
Journal:  Adv Drug Deliv Rev       Date:  2000-12-15       Impact factor: 15.470

2.  Grepafloxacin against penicillin-resistant pneumococci in the rabbit meningitis model.

Authors:  C M Gerber; L Tovar; M Cottagnoud; K A Neftel; M G Täuber; P Cottagnoud
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

Review 3.  The blood-brain barrier in neuroinflammatory diseases.

Authors:  H E de Vries; J Kuiper; A G de Boer; T J Van Berkel; D D Breimer
Journal:  Pharmacol Rev       Date:  1997-06       Impact factor: 25.468

4.  Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone.

Authors:  W M Scheld; R G Dacey; H R Winn; J E Welsh; J A Jane; M A Sande
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

5.  Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation.

Authors:  T Ooie; H Suzuki; T Terasaki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

6.  Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.

Authors:  M Tanaka; K Hoshino; M Hohmura; H Ishida; A Kitamura; K Sato; I Hayakawa; T Nishino
Journal:  J Antimicrob Chemother       Date:  1996-06       Impact factor: 5.790

7.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

Review 8.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

9.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

Review 10.  Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data.

Authors:  J Kawakami; K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1994-06
View more
  7 in total

1.  Lack of effect of experimental hypovolemia on imipenem muscle distribution in rats assessed by microdialysis.

Authors:  Sandrine Marchand; Claire Dahyot; Isabelle Lamarche; Elodie Plan; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Marc Pfister; Fernando Acosta; Marianne Cottagnoud; Lukas Flatz; Felix Kühn; Hans-Peter Müller; Armin Stucki
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Importance of Peptide transporter 2 on the cerebrospinal fluid efflux kinetics of glycylsarcosine characterized by nonlinear mixed effects modeling.

Authors:  Yeamin Huh; Scott M Hynes; David E Smith; Meihua R Feng
Journal:  Pharm Res       Date:  2013-02-01       Impact factor: 4.200

4.  Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.

Authors:  P Cottagnoud; M Pfister; M Cottagnoud; F Acosta; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

5.  Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat.

Authors:  Jessica E Chan; Tiffany A Pridgen; Karl G Csaky
Journal:  Exp Eye Res       Date:  2010-01-11       Impact factor: 3.467

6.  Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.

Authors:  Jun Shi; Marc Pfister; Stephen G Jenkins; Sunny Chapel; Jeffrey S Barrett; Ruedi E Port; Dan Howard
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 7.  Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.

Authors:  Jeffrey S Barrett; Line Labbé; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.